For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
It is official we are going virtual so save the dates April 22 – 25!
Two new fellowship opportunities from the University of British Columbia and BC Cancer: Glaxo Smith Kline Clinical Research Fellowship in Medical Oncology - Gynecologic Malignancies and the Miller Mindell Fellowship Gynecologic Oncology Research Fellowship
CommNETs hosted a virtual research workshop 10, 11, 16 and 17 February 2021 including a main conference event and five satellite project working group sessions. Thanks to the strong engagement of CommNETs collaborators, progress was made for planned work on existing projects and advancement of new ideas. CommNETs relies on the commitment of colleagues and partners to connect and lead research, and the continued collective effort of this group was evident through the excellent participation at the 2021 Virtual Research Workshop.
A Canadian team, Dr. Rebecca Auer Surgical Oncologist & Director of Cancer Research, The Ottawa Hospital and Dr. Chris O’Callaghan, Senior Investigator of the Canadian Cancer Trials Group are researching how we can strengthen the immune system of cancer patients to better protect them against COVID-19.
ExCELLirate Canada, led by the Canadian Cancer Trials Group (CCTG) at Queen’s University, has received $5,187,685 to develop a national research platform to coordinate the development of new cancer cell therapies. This will be a comprehensive national research, development and testing platform that will benefit patients, healthcare providers, and industry by ensuring Canadian cell therapy innovations are safely, cost effectively and efficiently manufactured.
The SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT): The Phase III Randomized Controlled Trial CCTG HN11 has successfully received $3,203,435 in funding from the Canadian Institutes of Health Research in the Fall Research competition.
Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition.
Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy. Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response.
Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received an additional $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Fall 2020 competition matching funds awarded in the spring from this program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada.
